TABLE 2.

Most common (>10% of patients) adverse events (AEs)

Preferred term	All patients N = 26 n (%)	Maximum severity grade
		Mild (grade 1) n (%)	Moderate (grade 2) n (%)	Severe (grade 3) n (%)
Patients with at least 1 AE	26 (100%)	2 (8%)	12 (46%)	12 (46%)
Diarrhea	11 (42%)	10 (38%)	1 (4%)	0
Fatigue	11 (42%)	6 (23%)	4 (15%)	1 (4%)
Hypertension	7 (27%)	3 (12%)	4 (15%)	0
Dizziness	7 (27%)	6 (23%)	1 (4%)	0
Insomnia	6 (23%)	6 (23%)	0	0
Nausea	5 (19%)	5 (19%)	0	0
Upper respiratory tract infection	6 (23%)	6 (23%)	0	0
Anemia	4 (15%)	0	2 (8%)	2 (8%)
Jaundice	4 (15%)	2 (8%)	1 (4%)	1 (4%)
Neutrophil count decreased	4 (15%)	2 (8%)	1 (4%)	1 (4%)
Pyrexia	4 (15%)	3 (12%)	0	1 (4%)
Cough	4 (15%)	4 (15%)	0	0
Headache	4 (15%)	3 (12%)	1 (4%)	0
Pain in extremity	4 (15%)	4 (15%)	0	0
Abdominal pain	3 (12%)	2 (8%)	1 (4%)	0
Alanine aminotransferase increased	3 (12%)	1 (4%)	2 (8%)	0
Alopecia	3 (12%)	2 (8%)	1 (4%)	0
Aspartate aminotransferase increased	3 (12%)	2 (8%)	1 (4%)	0
Atrial fibrillation	3 (12%)	1 (4%)	2 (8%)	0
Blood bilirubin increased	3 (12%)	0	3 (12%)	0
Constipation	3 (12%)	2 (8%)	1 (4%)	0
Dyspnea	3 (12%)	2 (8%)	1 (4%)	0
Arthralgia	3 (12%)	0	2 (8%)	1 (4%)
Hypokalemia	3 (12%)	1 (4%)	1 (4%)	1 (4%)
Muscle spasms	3 (12%)	2 (8%)	1 (4%)	0
Oropharyngeal pain	3 (12%)	3 (12%)	0	0
Rash	3 (12%)	2 (8%)	1 (4%)	0
Urinary tract infection	3 (12%)	1 (4%)	2 (8%)	0
Weight increased	3 (12%)	3 (12%)	0	0

Note: Patients are counted for the most severe event in a given row. Less common events (those occurring in <10% of patients) were not listed but contributed to the total number (top row).

Abbreviation: AE, adverse event.